151 related articles for article (PubMed ID: 32065901)
1. The financial impact of SBRT for oligometastatic disease: A population-level analysis in Belgium.
Nevens D; Kindts I; Defourny N; Boesmans L; Van Damme N; Engels H; Van de Voorde C; Lievens Y
Radiother Oncol; 2020 Apr; 145():215-222. PubMed ID: 32065901
[TBL] [Abstract][Full Text] [Related]
2. A review of ongoing trials of stereotactic ablative radiotherapy for oligometastatic disease in the context of new consensus definitions.
Li GJ; Arifin AJ; Al-Shafa F; Cheung P; Rodrigues GB; Palma DA; Louie AV
Ann Palliat Med; 2021 May; 10(5):6045-6051. PubMed ID: 32787370
[TBL] [Abstract][Full Text] [Related]
3. National costs and resource requirements of external beam radiotherapy: A time-driven activity-based costing model from the ESTRO-HERO project.
Defourny N; Perrier L; Borras JM; Coffey M; Corral J; Hoozée S; Loon JV; Grau C; Lievens Y
Radiother Oncol; 2019 Sep; 138():187-194. PubMed ID: 31319281
[TBL] [Abstract][Full Text] [Related]
4. Stereotactic body radiotherapy (SBRT) can delay polymetastatic conversion in patients affected by liver oligometastases.
Nicosia L; Cuccia F; Mazzola R; Figlia V; Giaj-Levra N; Ricchetti F; Rigo M; Bonù M; Corradini S; Tolia M; Alongi F
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2351-2358. PubMed ID: 32356176
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the prognostic value of the ESTRO EORTC classification of oligometastatic disease in patients treated with stereotactic body radiotherapy: A retrospective single center study.
Willmann J; Vlaskou Badra E; Adilovic S; Ahmadsei M; Christ SM; van Timmeren JE; Kroeze SGC; Mayinger M; Guckenberger M; Andratschke N
Radiother Oncol; 2022 Mar; 168():256-264. PubMed ID: 35101466
[TBL] [Abstract][Full Text] [Related]
6. Oligometastasis in breast cancer-current status and treatment options from a radiation oncology perspective.
Piroth MD; Krug D; Feyer P; Baumann R; Combs S; Duma MN; Dunst J; Fastner G; Fietkau R; Guckenberger M; Haase W; Harms W; Hehr T; Sedlmayer F; Souchon R; Strnad V; Budach W
Strahlenther Onkol; 2022 Jul; 198(7):601-611. PubMed ID: 35527272
[TBL] [Abstract][Full Text] [Related]
7. Oligometastatic Disease (OMD): The Classification and Practical Review of Prospective Trials.
Izmailov T; Ryzhkin S; Borshchev G; Boichuk S
Cancers (Basel); 2023 Oct; 15(21):. PubMed ID: 37958408
[TBL] [Abstract][Full Text] [Related]
8. Stereotactic Body Radiotherapy - Current Indications.
Burkoň P; Slavik M; Kazda T; Pospíšil P; Prochazka T; Vrzal M; Šlampa P
Klin Onkol; 2019; 32(1):10-24. PubMed ID: 30894002
[TBL] [Abstract][Full Text] [Related]
9. Disease course of lung oligometastatic colorectal cancer treated with stereotactic body radiotherapy.
Nicosia L; Cuccia F; Mazzola R; Ricchetti F; Figlia V; Giaj-Levra N; Rigo M; Tomasini D; Pasinetti N; Corradini S; Ruggieri R; Alongi F
Strahlenther Onkol; 2020 Sep; 196(9):813-820. PubMed ID: 32399637
[TBL] [Abstract][Full Text] [Related]
10. Development of a Prognostic Model for Overall Survival in Patients With Extracranial Oligometastatic Disease Treated With Stereotactic Body Radiation Therapy.
Chen H; Poon I; Atenafu EG; Badellino S; Biswas T; Dagan R; Erler D; Foote M; Redmond KJ; Ricardi U; Sahgal A; Louie AV
Int J Radiat Oncol Biol Phys; 2022 Dec; 114(5):892-901. PubMed ID: 34890753
[TBL] [Abstract][Full Text] [Related]
11. Health related quality of life outcomes following stereotactic body radiotherapy in patients with oligo-metastatic disease: A systematic review and individual patient data meta-analysis.
Barry AS; Helou J; Bezjak A; Wong R; Dawson LA; Ringash J; Fazelzad R; Liu Z; Olson R; Palma D; Ost P; Siva S; Phillips R; Adhikari NKJ
Radiother Oncol; 2022 Aug; 173():163-169. PubMed ID: 35680076
[TBL] [Abstract][Full Text] [Related]
12. Differences in United States Insurance Payer Policies and American Society for Radiation Oncology's (ASTRO) Model Policy on Stereotactic Body Radiation Therapy (SBRT).
Roach MC; Thomas TO; Paravati AJ; Mahajan A
Int J Radiat Oncol Biol Phys; 2019 Jul; 104(4):740-744. PubMed ID: 30677470
[TBL] [Abstract][Full Text] [Related]
13. Spanish Society of Radiation Oncology clinical guidelines for stereotactic body radiation therapy in lymph node oligometastases.
Conde-Moreno AJ; Lopez-Guerra JL; Macias VA; Vázquez de la Torre ML; Samper Ots P; San José-Maderuelo S; Pastor Peidro J; López-Torrecilla J; Expósito-Hernández J
Clin Transl Oncol; 2016 Apr; 18(4):342-51. PubMed ID: 26329294
[TBL] [Abstract][Full Text] [Related]
14. Stereotactic Body Radiotherapy in the Management of Oligometastatic Disease.
Ahmed KA; Torres-Roca JF
Cancer Control; 2016 Jan; 23(1):21-9. PubMed ID: 27009453
[TBL] [Abstract][Full Text] [Related]
15. Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Detected via Prostate-specific Membrane Antigen Positron Emission Tomography.
Kneebone A; Hruby G; Ainsworth H; Byrne K; Brown C; Guo L; Guminski A; Eade T
Eur Urol Oncol; 2018 Dec; 1(6):531-537. PubMed ID: 31158100
[TBL] [Abstract][Full Text] [Related]
16. The Influence of Health Insurance Policy on Radiation Oncology Physician SBRT/SABR Use Practices: A North American Survey.
Guo J; Kim H; Kalchman I; Dan TD; Zhan T; Werner-Wasik M
Int J Radiat Oncol Biol Phys; 2017 Nov; 99(3):524-529. PubMed ID: 29280445
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of stereotactic body radiotherapy to primary tumor and metastatic locations in oligometastatic nonsmall-cell lung cancer patients.
Collen C; Christian N; Schallier D; Meysman M; Duchateau M; Storme G; De Ridder M
Ann Oncol; 2014 Oct; 25(10):1954-1959. PubMed ID: 25114022
[TBL] [Abstract][Full Text] [Related]
18. Stereotactic body radiotherapy for lung cancer: how much does it really cost?
Lievens Y; Obyn C; Mertens AS; Van Halewyck D; Hulstaert F
J Thorac Oncol; 2015 Mar; 10(3):454-61. PubMed ID: 25376514
[TBL] [Abstract][Full Text] [Related]
19. Extracranial Stereotactic Body Radiotherapy in Oligometastatic or Oligoprogressive Breast Cancer.
Weykamp F; König L; Seidensaal K; Forster T; Hoegen P; Akbaba S; Mende S; Welte SE; Deutsch TM; Schneeweiss A; Debus J; Hörner-Rieber J
Front Oncol; 2020; 10():987. PubMed ID: 32676455
[No Abstract] [Full Text] [Related]
20. Completeness of Reporting Oligometastatic Disease Characteristics in the Literature and Influence on Oligometastatic Disease Classification Using the ESTRO/EORTC Nomenclature.
Nevens D; Jongen A; Kindts I; Billiet C; Deseyne P; Joye I; Lievens Y; Guckenberger M
Int J Radiat Oncol Biol Phys; 2022 Nov; 114(4):587-595. PubMed ID: 35738308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
